Influenza
Conditions
Keywords
Safety, Immunogenicity
Brief summary
One dose of escalating strengths of an investigational influenza vaccine, VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine), will be evaluated for safety and immunogenicity in healthy adults 65 to 75 years of age in this placebo-controlled study.
Detailed description
The purpose of this study is to evaluate, in a stepwise fashion, dose levels for an investigational quadrivalent influenza vaccine containing 2 influenza A strains and 2 influenza B strains. This is a multi-center, randomized, double-blind, placebo-controlled, dose escalating study in which up to 200 healthy adults age 65-75 years will be administered a single dose of either placebo or an investigational influenza vaccine (VAX2012Q, Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) at one of up to 3 dose levels. Fifty or up to 75 subjects will be enrolled in each dose level. Data for safety and immunogenicity will be collected for all dose levels.
Interventions
BIOLOGICALVAX2012Q
Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
OTHERPlacebo
Vaccine Diluent
Sponsors
VaxInnate Corporation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
65 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Males and females aged 65-75 years of age at the time of vaccination in good health. Individuals that are stably treated for hypertension may be eligible. * Able to provide informed consent * Willing to receive the unlicensed vaccine * Willing to provide multiple blood specimens * Live in the community, independently or in an assisted living environment * Based on the results of the Short Portable Mental Status Questionnaire be rated as normal or have no greater than mild severity dementia * As defined by the Canadian Study of Health and Aging Clinical Frailty Scale be a Class 1 to 5
Exclusion criteria
* Preceding the administration of study vaccine, has received or will receive 1) any licensed or investigational influenza vaccine product within 6 months, 2) any investigational drug or any investigational vaccine product other than influenza vaccine within the 30 days, 3) any licensed live vaccine other than influenza vaccine within 4 weeks, 4) any licensed inactivated vaccine other than influenza vaccine within 2 weeks * Planned receipt before the Day 21 blood draw of 1) any licensed or investigational influenza vaccine product, 2) any investigational drug or any investigational vaccine product other than influenza vaccine, 3) any licensed live vaccine other than influenza vaccine, 4) any licensed inactivated vaccine other than influenza vaccine * History of excessive alcohol use, drug abuse or significant psychiatric illness * Has a chronic illness that is not medically stable, is receiving a concomitant therapy in which the medication dose has not been stable for at least 3 weeks prior to immunization or has any other condition that could interfere with the subject's participation in the study or interpretation of the study results * Clinically significant abnormal liver function tests at screening * Subjects with Grade 2 or higher abnormalities in total bilirubin at screening * Subjects with any of the following laboratory abnormalities at screening: Creatinine \>1.7mg/dL, Hemoglobin \< 11g/dL for females; \<12.5 g/dL for males, WBC \<2500cell/mm3 or \> 15,000cell/mm3 and Platelet Count \<125,000cell/mm3 * Positive serology of HBSAg, HCV or HIV antibodies * Having cancer or have received treatment for cancer within three years, excluding minor skin cancers, which are allowed unless located at the vaccination site. Persons with a history of cancer who are disease-free without treatment for three years or more are eligible. * Persons with impaired immune responsiveness (of any cause), including Type 1 diabetes mellitus and auto immune disorders or any known or suspected autoimmune disease * Persons with congenital immunodeficiency or history of acquired immunodeficiency, or immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months. * Persons with a history of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component * Persons with a history of Guillain-Barré Syndrome * Receipt or donation of blood or blood products 8 weeks prior to vaccination or during the three week study period following vaccination * Acute disease within 72 hours prior to vaccination. * An oral temperature \>100.4°F (38°C) * Systolic blood pressure \< 85 mm Hg and subjects whose hypertension is untreated or unstable with antihypertensive therapy or that have systolic BP ≥ 160 mm Hg or diastolic BP ≥ 100 mm Hg requiring medical intervention with more than one drug or more intensive therapy than previously used or indicated. * Body Mass Index \>40 * Disorders of coagulation * Women less than 1 year post menopausal * A clinical diagnosis of influenza within the previous 6 months * Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Injection site and systemic symptoms will be collected for 21 days after vaccination. Other AEs assessed as related to vaccination will be collected at a 6 month and 1 year phone call. | 21 days post-immunization; follow up at 6 months and one year |
Secondary
| Measure | Time frame |
|---|---|
| Immune response to vaccine will be measured by serum HAI levels | 21 days post-immunization |
Countries
Australia
Outcome results
None listed